Cambridge Healthtech Institute’s Inaugural

Target Identification and Validation – Part 1

Proteomics-Based Target Discovery

September 16-17, 2020


Finding novel, druggable targets for therapeutic intervention remains a top priority for the pharma/biotech industry. It also remains a formidable challenge and companies continue to invest a lot of time and resources in identifying and validating targets that will yield viable drugs. How are genomics and proteomics helping overcome some of the challenges in target discovery today? What new tools and strategies are being employed and how well are they working? What’s being done to adequately validate the targets once they are identified? What efforts are being taken to go after difficult or “undruggable” targets? Cambridge Healthtech Institute’s conference on Target Identification and Validation will bring together leading experts to discuss some of these critical issues. This is a unique opportunity to meet and network with biologists and screening groups from around the world to share ideas and best practices.

Besides target identification, target deconvolution and validation are also equally challenging and remain important bottlenecks in drug discovery. Chemical biology, particularly chemoproteomics and other mass spectrometry-based tools and assays are playing an important role in identifying, evaluating, and prioritizing new drug targets. The first part of the Target Identification and Validation conference focuses on Proteomics-Based Target Discovery that leverages these new chemical probes, assays, and screening tools being developed.

Preliminary Agenda


KEYNOTE PRESENTATION: Reimagining Druggability Using Chemoproteomic Platforms

Daniel Nomura, PhD, Professor of Chemistry, Molecular and Cell Biology, and Nutritional Sciences and Toxicology, University of California Berkeley

Reimagining Fragment-Based Multiplexed Chemical Proteomics for Cell-Based Screening of Large Electrophile Libraries

Steve Gygi, PhD, Professor, Department of Cell Biology, Harvard Medical School

Chemoproteomic Strategies for Target Discovery and Evaluation

Brent Martin, PhD, Senior Principal Scientist, Chemical Biology/Chemoproteomics, Molecular & Cellular Pharmacology, Janssen R&D


Application of CETSA Technology in Target Deconvolution

Gizem Akcay, PhD, Senior Scientist, Chemical Biology, AstraZeneca

Chemical Probe Utilization for Kinase Target Occupancy Measurement in Periphery and CNS

Bekim Bajrami, PhD, Senior Scientist, Chemical Biology and Proteomics, Biogen Inc.

Proteomics as a Tool for Target Identification and Target Engagement

Ryan McClure, PhD, Senior Scientist, Drug Discovery Science & Technology, Abbvie

Integration of Chemical and Phosphoproteomics for Dissecting Network Pharmacology

Uwe Rix, PhD, Associate Member, Department of Drug Discovery, Moffitt Cancer Center


Using Enzymatic Site-Specific Modification to Enable Analysis of RNA-Protein Interactions and Enrichment of Cellular RNA

Neal Devaraj, PhD, Professor, Departments of Chemistry, Biochemistry and Bioengineering, University of California San Diego

Chemoproteomic Approaches to Profile RNA Binding and Modifying Proteins

Ralph Kleiner, PhD, Assistant Professor of Chemistry, Princeton University


Computational and Experimental Exploration of Novel Drug Targets Using Phenotypic Screens

Yuan Wang, PhD, Senior Principal Scientist, Head of TPD Data Science, UCB Pharma

Identification of Novel Target and Biology from Human Macrophage Repolarization Screen

Sreemanti Basu, PhD, Senior Scientist, Drug Discovery Science and Technology, Abbvie

Please click here to continue to the agenda for Target Identification and Validation – Part 2

For more details on the conference, please contact:
Tanuja Koppal, PhD

Senior Conference Director

Cambridge Healthtech Institute



For partnering and sponsorship information, please contact:
Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-6286